Home/Filings/4/0001209191-09-051752

4//SEC Filing

MPM BIOVENTURES III QP LP 4

Accession 0001209191-09-051752

CIK 0000755806other

View on SEC.gov Company Profile

Filed

Nov 8, 7:00 PM ET

Accepted

Nov 9, 6:55 PM ET

Size

23.1 KB

Accession

0001209191-09-051752

Insider Transaction Report

Form 4

Period: 2009-11-05

PONIARD PHARMACEUTICALS, INC.PARD

MPM BIOVENTURES III LLC

10% Owner

Transactions

Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)
Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)

MPM BIOVENTURES III GP LP

10% Owner

Transactions

Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)
Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)

MPM BIOVENTURES III GMBH & CO. Beteiligungs KG

10% Owner

Transactions

Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)

MPM Asset Management Investors 2005 BVIII LLC

10% Owner

Transactions

Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)
Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)

MPM BIOVENTURES III PARALLEL FUND, LP

10% Owner

Transactions

Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)
Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)

MPM BIOVENTURES III LP

10% Owner

Transactions

Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)
Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)

MPM BIOVENTURES III QP LP

10% Owner

Transactions

Sale
Common Stock
2009-11-06$8.06/sh−264,648$2,132,560→ 6,515,301 total(indirect: See Footnote)
Sale
Common Stock
2009-11-05$8.00/sh−78,262$626,292→ 6,779,949 total(indirect: See Footnote)
Sale
Common Stock
2009-11-09$8.50/sh−152,052$1,292,442→ 6,363,249 total(indirect: See Footnote)

Footnotes (9)

[F1]The shares were sold as follows: 65,236 by MPM BioVentures III-QP, L.P. ("BV III QP"), 4,387 by MPM BioVentures III, L.P. ("BV III"), 1,155 by MPM Asset Management Investors 2005 BVIII LLC ("AM 2005"), 1,971 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 5,513 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. and MPM BioVentures III LLC ("BV III LLC") are the direct and indirect general partners of BV III QP, BV III , BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Michael Steinmetz, Dennis Henner, Nicholas Simon III, and Kurt Wheeler are members of BV III LLC and AM 2005. Mr. Simon is a director of the Issuer and files reports seperately.
[F2]The shares were sold at prices ranging from $8.00 to $8.0175. The Reporting Persons will provide, upon request to the SEC, the Issuer or securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
[F3]The shares are held as follows: 5,651,531 by BV III QP, 380,015 by BV III, 100,106 by AM 2005, 170,718 by BV Parallel and 477,579 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
[F4]The shares were sold as follows: 220,601 by BV III QP, 14,833 by BV III, 3,908 by AM 2005, 6,664 by BV Parallel and 18,642 by BV KG.
[F5]The shares were sold at prices ranging from $8.00 to $8.17. The Reporting Persons will provide upon request to the SEC, the Issuer or securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
[F6]The shares are held as follows: 5,430,930 by BV III QP, 365,182 by BV III, 96,198 by AM 2005, 164,054 by BV Parallel and 458,937 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
[F7]The shares were sold as follows: 126,745 by BV III QP, 8,522 by BV III, 2,245 by AM 2005, 3,829 by BV Parallel and 10,711 by BV KG.
[F8]The shares were sold at prices ranging from $8.50 to $8.51. The Reporting Persons will provide upon request to the SEC, the Issuer or securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
[F9]The shares are held as follows: 5,304,185 by BV III QP, 356,660 by BV III, 93,953 by AM 2005, 160,225 by BV Parallel and 448,226 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Documents

1 file

4
c92353_4x0.xmlPrimary
MAIN DOCUMENT DESCRIPTION

Issuer

PONIARD PHARMACEUTICALS, INC.

CIK 0000755806

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001173409

Filing Metadata

Form type: 4
Filed: Nov 8, 7:00 PM ET
Accepted: Nov 9, 6:55 PM ET
Size: 23.1 KB

View on SEC.gov